---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-194428"
form_type: "8-K"
ticker: "SNSE"
cik: "0001829802"
company_name: "Sensei Biotherapeutics, Inc."
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:33:25.452868+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Sensei Biotherapeutics Q2 net loss $7.1M; cash $52.3M; SNS-101 dose expansion on track

## Summary
- Net loss $7.1M vs $9.4M in Q2 2023; R&D $4.6M (-$0.2M), G&A $3.2M (-$2.2M).
- Cash $52.3M, expected to fund operations into Q4 2025.
- Phase 1/2 SNS-101 dose expansion enrollment advancing; initial data Q4 2024; end-of-Phase 1 FDA meeting by year-end.
- ASCO 2024 data showed well-tolerated safety, best-in-class PK, and early clinical activity.
- Appointed Josiah Craver as SVP of Finance, effective July 22, 2024.

## SEC filing metadata
- accession: 0001193125-24-194428
- form_type: 8-K
- ticker: SNSE
- cik: 0001829802
- company_name: Sensei Biotherapeutics, Inc.
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829802/000119312524194428/0001193125-24-194428-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829802/000119312524194428/d862389d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-194428
- JSON: https://secwatch.observer/filing/0001193125-24-194428.json
- Plain text: https://secwatch.observer/filing/0001193125-24-194428.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.